The NOVA trial showed that niraparib was effective in patients with platinum-sensitive ovarian cancer, demonstrating that PARP inhibitors are effective in carriers of mutations other than BRCA1 and BRCA2 [24]. The gene discussed is BRCA2; the disease is ovarian cancer.